Oncolytics Biotech Inc ONCY

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

[Buckhenry]

The news just couldn't be better. Good things are promised by canuckfan etal... delisting letter being drafted now. 

[itntdf]

https://www.morningstar.com/news/globe-newswire/9156522/pancreatic-cancer-market-is-projecting-to-expand-as-nci-funded-research-expects-to-empower-market-growth

[Noteable]

"The first half of 2024 shows how the industry has learned to execute accretive deals in the face of persistent headwinds,” the PwC report’s authors concluded. “  "So what’s driving

[canadafan]

Obviously no end of day support today. nice nr today, more to come

[inthno]

Thank heavens for that end of day support. Having said that, it was a good pr and one we were expecting. Still need the partnership or bo to move the sp and that's all there is to it.

[ENEMENEMYNEMO]

Read ??? I'm too busy for that... that's what you are for.  Thanks for the info Aardvark!

[Azzak34]

Somebody can't read!!! Results are in end of 2nd quarter and we get readout towards the end of the 3rd. This was stated fairly clearly. 

[Azzak34]

Again Quenty. Which ones, what should our entry points be? Please give us specifics so we can all see your utter garbage un real time?  How's your BTC holdings doing? Bahaha

[canadafan]

Nice view Noteable. The $5m to $15 m sweet spot discussion. Additionally explaining they are looking for scientific opportunities, not necessarily financial. Yesterday I had an unrelated ( to do

[Quentin30]

sell half, if at a loss if need be... invest in next gen technology...  gene editing...  wait 12 months... be thankful... because chances are, ONCY will still be talking potential, and

[ENEMENEMYNEMO]

1) When's the date? 2) Were they not supposed to provide final Bracelet Data in Q2??

[Noteable]

June 20, 2024 - "“As dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in

[Jonathon Brown]

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. read article.

[PressRelease]

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefitFunding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCANSAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire...read article.

[canadafan]

So you are telling me the I.R. Communications from Onc, does not know how to spell the word "I" Really? im not a good speller , myself. However I'm not a communications executive.